<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Umbilical cord blood (UCB) has increased access to hematopoietic cell transplantation (HCT) for patients without HLA-matched sibling donors (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We compared outcomes of HCT using <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> (N=38) or UCB (N=60) among older patients (age â‰¥ 55 years) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received a reduced intensity regimen consisting of CY, fludarabine and 200 cGy TBI </plain></SENT>
<SENT sid="3" pm="."><plain>Median age at HCT was 63 years for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> and 61 years for UCB recipients </plain></SENT>
<SENT sid="4" pm="."><plain>Among UCB recipients, 95% received two UCB units and 88% received 1-2 locus HLA-mismatched units to optimize cell dose </plain></SENT>
<SENT sid="5" pm="."><plain>OS at 3-years was 37% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> and 31% for UCB recipients (P=0.21) </plain></SENT>
<SENT sid="6" pm="."><plain>On multivariate analysis, donor source (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> vs UCB) did not impact risks of OS, <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival and relapse or treatment-related mortality </plain></SENT>
<SENT sid="7" pm="."><plain>UCB is feasible as an alternative donor source for reduced-intensity conditioning HCT among older patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who do not have a suitable <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> </plain></SENT>
</text></document>